Rosmarinic acid prevents fibrillization and diminishes vibrational modes associated to β sheet in tau protein linked to Alzheimer’s disease

Alberto Cornejo, Felipe Aguilar Sandoval, Leonardo Caballero, Luis Machuca, Patricio Muñoz, Julio Caballero, George Perry, Alejandro Ardiles, Carlos Areche and Francisco Melo

ABSTRACT
Alzheimer’s disease is a common tauopathy where fibril formation and aggregates are the hallmark of the disease. Efforts targeting amyloid-β plaques have succeeded to remove plaques but failed in clinical trials to improve cognition; thus, the current therapeutic strategy is at preventing tau aggregation. Here, we demonstrated that four phenolic diterpenoids and rosmarinic acid inhibit fibrillization. Since, rosmarinic acid was the most active compound, we observe morphological changes in atomic force microscopy images after treatment. Hence, rosmarinic acid leads to a decrease in amide regions I and III, indicating that rosmarinic acid prevents β-sheet assembly. Molecular docking study inside the steric zipper model of the hexapeptide 306VQIVYK311 involved in fibrillization and β sheet formation, suggests that rosmarinic acid binds to the steric zipper with similar chemical interactions with respect to those observed for orange G, a known pharmacofore for amyloid.

Introduction
Alzheimer’s disease (AD), the most common form of dementia, is characterized by the deposition of two main protein aggregates in the brain: senile plaques consisting of amyloid-β (Aβ) and neurofibrillary tangles (NFTs) composed mainly of the microtubule-associated protein tau and found as intraneuronal inclusion. Tau protein also plays an important role in other tauopathies, such as progressive nuclear palsy (PSP), corticobasal degeneration (CBD), and Pick’s disease. In these tauopathies, tau is located in neurons and glia. Physiologically, tau regulates microtubule stability and axonal transport, but in patients with AD it becomes increasingly phosphorylated. Hyperphosphorylated tau no longer binds to microtubules and accumulates in the soma and dendrites of neurons, forming intracellular deposits called paired helical filaments (PHFs) that are the main fibril component of NFTs. Tau pathology occurs concomitantly with axonal transport deficits and neuronal degeneration.

On the other hand, human tau is a natively unfolded protein whose structure has two fibril-forming motifs, 275VQIINK280 and 306VQIVYK311. These motifs are within the microtubule-binding domain (4R) of tau (aa 244–373), and are frequently used to resemble tau aggregation in vitro. Crystallization of the fibril-forming motifs shows that they are both necessary and sufficient for tau fibrillization. In particular, the glutamine residue in the 306VQIVYK311 hexapeptide is essential for tau fibrillization. The hexapeptide 275VQIINK280 is of equal importance for tau fibril formation; unfortunately no crystal structure is available. The protein secondary structure with the highest tendency to form fibrils are β sheets that can associate adjacent strands running either parallel or antiparallel. The 306VQIVYK311 hexapeptide forms parallel β sheets that are linked through interdigitating non-polar side chains. The correlation of pathological phosphorylation of tau triggers conformational changes that make it prone to form dimers or higher oligomers. Interestingly, improvement in the cognition of a transgenic mouse model displaying both NFTs and senile plaques required reduction of soluble tau but not of Aβ plaques. Over-expression of tau in neurons has deleterious effects, suggesting that intracellular tau aggregates are cytotoxic.

The major focus of past drug developments for AD treatment has rested on Aβ, although a significant number of candidate drugs have failed to slow down disease progression. For example, immunization against Aβ was effective in reducing amyloid plaque load, but had little effect on cognitive functions in patients. Moreover, a recent study shows that gamma-secretase inhibition failed in a clinical phase III trial. Thus, it seems timely to consider alternate drug discovery strategies for AD, based on approaches such as misfolded tau reducing agent. The development of small-molecules that inhibit aggregation of tau appears as a valid alternative strategy for developing new treatments for AD and other tauopathies. It has been proposed that naturally occurring phytochemicals have the potential to prevent AD based on their neuroprotective, anti-amyloidogenic, anti-oxidative and anti-inflammatory properties. For instance, natural polyphenols have reported anti-aggregating capacity to prevent amyloid formation, and a standardized turmeric extract reduced both amyloid-β and phosphorylated tau levels in a transgenic mouse...
model. Likewise, novel compounds have been found with the ability to prevent tau aggregation, such as cinnamon extract, and fulvic acid among others. *Rosmarinus officinalis* L. belonging to Lamiaceae family has been used in medicine as anti-inflammatory and antimicrobial agent. Since drugs targeting Aβ have recently failed in clinical trials, it seems timely to search for other naturally occurring polyphenols with relevant activities, such as tau inhibitors. Considering that tau pathology involves not only AD but several tauopathies, we investigated the effect of four phenolic diterpenes and one caffeoyl derivative, isolated from *Rosmarinus officinalis* L., over heparin-induced tau aggregation in vitro by using thioflavin T assay (ThT), atomic force microscopy (AFM), and Raman spectroscopy. In addition, we provide structure-based models of complex between the fibril-forming motif \(^{306}\text{VQIVYK}\)\(^{311}\) of tau and caffeoyl derivative to explain the mechanism of its tau anti-aggregation capacity.

**Materials and methods**

**Chemistry**

Silica gel (Kieselgel 60, Merck 0.063–0.200 mm) and Sephadex LH-20 were used in column chromatography (CC). Technical solvents used in extraction were previously distilled and dried according to standard procedures. The extraction and purification of 1, 2, 3, 4, and 5 were carried out essentially as described. The purity of all compounds was estimated by using a HPLC-PDA (>98%) (Agilent LC-1200). Tau 4R (four microtubule binding domain) recombinant protein was expressed in *E. coli*. The expressed protein was purified by HPLC using a ProPac IMAC-10 Column. Aggregation and fluorescence assays were performed in a Biotek H1 monochromator-based multi-mode microplate reader. Samples were prepared on highly ordered pyrolytic graphite (HOPG) as substrate, and atomic force images were obtained using a Nanoscope III equipment in tapping mode. Raman spectra and maps were obtained through a Confocal Raman Microscopy Alpha 300 (WiTec GmbH).

**General experimental procedures of extraction and isolation**

*Rosmarinus officinalis* L. was collected in Talca, VII Región, Chile. Samples from aerial parts were dried at room temperature in darkness. *R. officinalis* L. was identified by Prof. O. García, and a voucher specimen (No. RO-2015/1215) is kept at the Herbarium of Extreme Natural Product Laboratory of University of Chile. Dried and pulverized leaves of *R. officinalis* L. (1000 g) were extracted at room temperature using methanol (3 times, 3 L each time). The resulting solution was evaporated under vacuum to yield 65 g of extract, which was subjected to Sephadex LH-20 (4 times, 10 × 100 cm) using methanol as mobile phase giving four fractions A–D. The only fractions studied were of medium polarity (C–D). Fraction C (15 g) was subjected to column chromatography on silica gel (12 × 90 cm, 63–200 μm) with mixtures of hexane containing 10% increments of ethyl acetate to yield 9 fractions. A crude mixture of phenolic diterpenoids was detected on TLC (Liebermann reactive) eluting with 50% ethyl acetate in hexane (fraction 5). After repeated CC on silica gel of Fr 5, the phenolic diterpenes carnosol (1) (2 g), carnosic acid (2) (800 mg), rosmanol (3) (8 mg), and the mixtures of rosmanol 3 and episerosmanol 4 were isolated. Compounds 3 (6 mg) and 4 (9 mg) were further purified by a preparative RP-HPLC (PrepCHROM C-700, BÜCHI) using as mobile phase H₂O–MeOH (9:1, 8:2, 7:3, 6:4; 5:5; 4:6, 3:7, 2:8, 1:9).

Fraction D (5 g) was fractionated by CC on silica gel (5 × 60 cm, 63–200 μm) eluted with methanol in dichloromethane giving 3 fractions (A–C). Fractions of interest were monitored by DPPH (5% in MeOH). Some 200 mg of fraction C were further purified by a preparative RP-HPLC using as mobile phase H₂O–MeOH (9:1, 7:3, 5:5; 3:7, 1:9) to give rosmarinic acid (5) (150 mg).

**Protein expression and purification of tau 4R**

The fragment 4R (htau244-372) was cloned into pET-28a vector (Novagen) to produce a His-tagged protein which was expressed in *Escherichia coli* strain BL21 (DE3) as described. LB medium containing kanamycin (30 μg/ml) was inoculated with a stationary overnight culture. The culture was grown at 37°C to OD₆₀₀ of 0.5–0.6, and protein expression was induced by addition of 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) for 4 h. The cells were pelleted and then resuspended in 50 ml of buffer A (50 mM sodium phosphate buffer pH 7.4, 500 mM NaCl, and 20 mM imidazole) supplemented with EDTA free anti protease tablet (Roche). The mixture was sonicated for 5 min, centrifuged at 10000 g for 30 min and then filtered (0.22 μm membrane filter, Millipore). The sample was loaded onto ProPac IMAC-10 Column (4 × 250 mm Thermo dionex) with buffer A and buffer B (50 mM sodium phosphate buffer pH 7.4, 500 mM NaCl, 200 mM imidazole). After loading, one-step wash with 30 mmol imidazole (7.7% B) was done before elution at 200 mmol imidazole. Protein purity was verified on Coomassie Brilliant Blue-stained SDS-polyacrylamide gel. The concentration of purified 4R was determined using the extinction coefficient at 280 nm (1520 M⁻¹ cm⁻¹). The concentrated protein was stored at −80°C until use.

**Tau fibrillization in vitro**

The aggregation of 4R was induced with 40 mM of protein plus 10 μM of heparin in 100 mM of sodium acetate pH 7.0 for 24 h incubation time, with continuous shaking. Standard solution of 5 at 10 mM to 1 mM (DMSO) was prepared fresh prior to aggregation experiments. We used a black flat bottom 96 well plate (ThermoFisher scientific).

**Atomic force microscopy images of tau protein**

Each sample was prepared by pipetting 30 μL (40 μM of tau plus 10 μM of heparin) in the presence or absence of 5 (10 μM and 1 μM respectively) onto highly orientated pyrolytic graphite (HOPG). The samples were incubated at room temperature for 30 min and then carefully washed. Atomic force microscopy imaging was performed in tapping mode using a Nanoscope III (Veeco, CA) and Olympus AC240TS cantilevers exhibiting spring constants of 2 N/m at resonance frequencies of 55 kHz. To achieve minimal imaging forces between AFM stylus and sample, the drive amplitude was set between 0.5 and 1.0 V, and the amplitude set point was adjusted manually to compensate for the thermal drift in order to maintain good tracking of the sample.

**ThT binding fluorescence assay of tau protein**

The ThT fluorescence assay adopted here was modified from the reported by Pickhardt et al. and Crowe et al. Briefly, to examine the inhibition of tau aggregation, the total volume of the reaction...
mixture was 100 μL, which included 40 μM of protein, 10 μM heparin in 100 mM sodium acetate, pH 7.0 plus 5 at different concentrations. Notice that for inhibition all components are included in the solution at the same time. After 24 h incubation time at 37°C, addition of 100 μL at a 50 μM solution of ThT was made and incubation continued for 1 h at room temperature prior to fluorescence reading. Then, the fluorescence was measured in a BioTek Synergy H1 multimode-multiple reader with an excitation wavelength at 440 nm and emission wavelength of 485 nm in a 96-well plate.

**Raman spectra and maps of tau β sheets content**

The Raman spectra of 4R were recorded as described with modifications by using an Confocal Raman Microscope Alpha 300 (WITec GmbH) equipped with a solid state Compass Sapphire laser (Coherent Inc.) operating at 532 nm and a Back Illuminated CCD camera DV401A (Andor Technology Ltd.) cooled at -60°C. A single mode 3.5/125 μm optical fiber was used (OZ Optics Ltd.) to connect the laser to a Zeiss (100X/0.9 NA) objective. The laser power was set between 10 to 20 mW. In order to generate scan images, we set 20 points per line over a surface of 5 μm (width) and 5 μm (height). Scan speed was set to 100 s/line. Integration time was set to 5 s. Tau protein sample (40 μM plus 10 μM of heparin) over glass (microscope slides) was dried and the spectra collected on several spots over the sample. The sample spectra were standardized from glass (spectra subtracted).

**Molecular docking of 306VQIVYK311 fragment of tau and 5**

Docking was performed by using the Glide method. A grid box of 15 Å × 10 Å × 10 Å covered the whole cavity in the model. Docking parameters were used as in previous work, and Glide extra-precision (XP) modes were explored during the search. The docking hierarchy begins with the systematic conformational expansion of the ligand followed by placement in the receptor site. Then minimization of the ligands (R and S enantiomers) in

---

**Figure 1.** (a) Structure of 1, 2, 3, 4, and 5 isolated from *Rosmarinus officinalis* L.

**Figure 2.** Thioflavine ThT assay over tau fibrillization. (A) Four phenolics diterpenoids, 1, 2, 3, 4, and a caffeoyl derivative 5 were challenged against tau aggregation at 50 μM. All compounds were active as inhibitors against tau aggregation. Data were presented as mean ± SEM and analyzed using ANOVA. Significance was set as p < 0.05.

![Thioflavine ThT assay](image1)

**Figure 3.** Dose–response effect of 5 over tau 4R aggregation process monitored by ThT. Serial concentration of 5 between 10 μM and 100 μM. B) To obtain IC50 the curve fit method was set as non-linear regression. IC50 calculated correspond to 7.7 μM. Data were presented as mean ± SEM and analyzed using paired t-test showed there was a significant differences between control and treatment conditions t (8) = 13.406, p < 0.05.

---

| Natural compounds | Inhibition (%) |
|-------------------|---------------|
| 1                 | 68            |
| 2                 | 65            |
| 3                 | 50            |
| 4                 | 70            |
| 5                 | 84            |

**Table 1.** Table of Inhibition (%) among phenolic diterpenoids (1,2,3,4) and caffeoyl derivative (5). All compounds inhibit over 50%, including the most active compound 5 (84%).
the receptor field were carried out using the OPLS-AA force field with a distance-dependent dielectric of 2.0. Afterwards, the lowest energy poses were subjected to a Monte Carlo procedure that samples the nearby torsional minima. The best pose for a given ligand was determined by the Emodel score, while different compounds were ranked using GlideScore. The docking poses were analyzed by examining their relative total energy score. The more energetically favorable conformations were selected as best poses.

**Statistical analysis**

Statistical analysis was developed using Graphpad 6. Data were analyzed as Mean ± SE using Paired t-test and Anova. Significance was determined as \( p < 0.05 \).

**Result and discussion**

Phenolic diterpenes and caffeoyl derivative inhibit fibrillization of tau monitored by ThT fluorescence assay

Interestingly, some phenolic diterpenoids such as carnosic acid has been reported as a potent activator of a nuclear factor erythroid 2 related transcription factor (Nrf-2), a major regulator of redox homeostasis in mammals, whose activity relies on a catechol moiety. Also phenolic diterpenoid carnosic acid has shown effects on A\(\beta\) peptides production in a cells model. Another phenolic diterpenoid, carnosol, has been reported as an anti-inflammatory and anti carcinogenic agent, and blocked inactivation of muscarinic acetylcholine receptor.

Moreover, rosmarinic acid isolated from the spice sage (Salvia officinalis) protects PC12 cells from neurotoxicity induced by amyloid-\(\beta\) and has protective effects on transgenic mice carrying a double mutation linked to an amyloid precursor protein. However, until now neither phenolic diterpenoids, nor 5 have been tested against tau aggregation. Thus, we isolated 1, 2, 3, 4, and 5 from Rosmarinus officinalis, in order to demonstrate whether they may act as tau inhibitors by avoiding fibril formation in vitro and subsequent \(\beta\) sheet sheet formation. The chemical structure of phenolic diterpenoids is shown in Figure 1. The \(^{1}\)H-NMR spectrum of 1, 2, 3, 4, and 5 is consistent with the literature. Tau protein largely exists as an intrinsically disordered protein; however as long as motifs 275VQIINK280 and 306VQIVYK 311 interact, tau is able to form paired helical filaments with cross \(\beta\)-sheets. In addition, the benzothiazole dye, ThT, has been used as a fluorescence marker for amyloid fibrils; giving a reliable signal to determine fibril content in vitro. Therefore, we address the question of whether both phenolic diterpenoids and 5 are able to stop aggregation of tau by carrying out ThT fluorescence assay as an indicator of fluorescence intensity associated to aggregation. Thus, we demonstrate that all compounds are able to inhibit tau aggregation at 50 \(\mu\)M (Figure 2(A)). Considering the inhibition percentage, all naturally occurring compounds inhibit over 50%, and the most active compound was 5 (Table 1). Since 5 was the most effective compound, supplemental assays are performed in order to provide understanding of how 5 interacts with tau. First, we

![Figure 4](image-url)
induced tau fibrilization and then we added 5 at different concentrations, after incubation we measured fluorescence intensity. Thus, we found that 5 inhibits tau in concentrations ranging from 10 μM to 100 μM, in dose-response manner (Figure 3(A)). In addition, we calculated IC\textsubscript{50} at 7.7 μM of 5 based on a nonlinear regression method (Figure 3(B)).

It is important to note that nitrocatechol derivatives such as tolcapone and entacapone exhibit anti-aggregation properties against both Aβ and α-synuclein and tau hexapeptide\textsuperscript{54-55}.

Considering that 5 was the most active compound and it has two catechol moieties, we hypothesize that differences observed can be evidence of a main role of catechol moiety.

**Compound 5 diminishes fibril formation and reduces band assignment modes associated to β-sheets**

The hallmark of Alzheimer’s disease and tauopathies is the formation of paired helical filaments and subsequent fusion into neurofibrillary tangles (NFTs) whose core is mainly composed of β-sheets structure\textsuperscript{56}. Moreover, kinetic studies of fibril formation by using ultraviolet resonance Raman (UVRR) spectroscopy have revealed different stages in fibrillation where at early stages it is possible to find fibrillary aggregates with β sheet and disordered content. As the process advances, the β sheet content also increases\textsuperscript{57}. Therefore, there is a correlation between Raman spectroscopy, band assignment, and secondary structure\textsuperscript{58}. The sensitive Amide I region is associated with C=O stretch and is able to form a hydrogen bond with an N–H group of either inter- or intra-backbone chain giving a good signature of a β-sheet between wavenumbers 1674–1670 cm\textsuperscript{-1}. Moreover, Amide III region is associated to C–N stretching and N–H bending giving a β-sheet signature in the range of wavenumber 1242–1227 cm\textsuperscript{-1}. Hence, Raman spectroscopy provides a useful method to monitor β sheet formation\textsuperscript{59}.

Considering that 5 was the most active naturally occurring compound that we isolated from *R. officinalis*, we elucidate whether there are both morphological and signature changes in secondary structure once 5 interacts with tau protein. With this in mind, we induce tau aggregation by adding heparin, which promotes paired helical fibril formation. Atomic force microscopy images (Figure 4) show several twisted fibrils and oligomers at two distinct magnifications. Aggregation control experiments are presented in Figure 4(A) and in Figure 4(D) with higher magnification. Interestingly, once we challenge tau aggregation with 5 at 1 μM, a few straight-thin filaments and several oligomers are seen on the HOPG surface (Figure 4(B,E)). However, at 10 μM of 5 most fibrils and oligomers are diminished indicating that 5 is able to prevent fibril progression (Figure 4(C,F)). Raman’s spectra of tau aggregation (24 h) and Raman vibrational bands are both shown in Figure 5(A), and the vibrational modes are listed in Table 2. Figure 5(A) shows band assignments associated to Amide I and Amide III that are linked to β sheets. In addition, we found band assignment associated to C–H deformation at 1451 cm\textsuperscript{-1} (Figure 5(A)). However, the spectra of tau aggregation in the presence of 5 (10 μmol) (Figure 5(B)), clearly shows a band assignment reduced in both Amide I and III region, respectively, and a signal corresponding to disordered structure at 1260 cm\textsuperscript{-1} is also detected, indicating that 5 prevents fibrillization and diminished β-sheet content. Considering that tau is a natively unfolded protein, this suggests that some tau protein at least remains in the disordered state (Figure 5(B)), differently from tau in absence of 5, where we found a massive peak at 1670 cm\textsuperscript{-1} indicative of β sheet antiparallel structure. Interestingly, inhibitors with a nitrocatechol moiety are able to prevent aggregation and β-sheets assembly as demonstrated by circular dichroism\textsuperscript{55}.

Raman maps based on the integral of different Raman bands give the relative intensities of defined peaks in the spectral region. Thus, we analyzed peaks associated to β sheets (Amide I and III), and C–H deformation. As we compared aggregation control, with samples treated with 5, there are differences between peak intensities, including Amide I (1670 cm\textsuperscript{-1}) (Figure 6(B,D)), and Amide III (1240 cm\textsuperscript{-1}) (Figure 6(C,E), respectively), indicating that relative intensities associated to β sheets are also diminished. However, once we compare C–H deformation (1451 cm\textsuperscript{-1}) in both controls and treated sample, significant differences were not found (Figure 6(A,D)), indicating that sample amounts remain similar in both (control and treated) once we scan over the glass surface to determine Raman spectra.

**Molecular modeling of 5 binding to tau’s 306VQIVYK\textsuperscript{311} hexapeptide**

Tau is considered a natural unstructured protein\textsuperscript{35}, although there is limited information on its exact structure. However, the
structure of the fibril-forming hexapeptide motif of tau, $^{306}\text{VQIVYK}^{311}$, has been resolved by X-ray crystallography in complex with orange-G (Protein Data Bank code 3OVL). Orange-G is bound between steric zippers of VQIVYK with its long axis parallel to the fiber axis and forms salt links between its sulfonic acid groups and lysine ammonium ions from repeating strands in VQIVYK fibers. In addition, the aromatic rings of orange-G are packed against apolar side chains of Val309, and establish polar interactions with glutamine and lysine side-chains at the edges of the steric zipper. Recent works have used the information of the VQIVYK-orange-G crystals to propose interactions between ligands that prevent tau aggregation and the hexapeptide VQIVYK using docking method.

Compound 5 has an elongated shape, aromatic and polar groups, and a negatively charged group, which match with the chemical features orange-G. With this in mind, we propose that rosmarinic acid inhibits tau aggregation by establishing chemical interactions with the fibril-forming hexapeptide VQIVYK.

To obtain a better understanding of a possible interaction of 5 with the $^{306}\text{VQIVYK}^{311}$ motif in 4R oligomers, we model 5 binding (R and S enantiomers were considered) to $\beta$-sheets of poly-$^{306}\text{VQIVYK}^{311}$ hexamers. X-ray crystallography revealed that fiber-like complexes of $^{306}\text{VQIVYK}^{311}$ consist of pairs of $\beta$-sheets, allowing small molecules to bind between sheets. In particular, negatively charged molecules bound specifically to $^{306}\text{VQIVYK}^{311}$ lysine side chains of adjacent sheets. Rosmarinic acid docking was done inside the cylindrical cavity formed by paired $^{306}\text{VQIVYK}^{311}$ $\beta$-sheets (Figures 7(A,B)).

Our docking models depict that both 5 enantiomers are placed inside the cavity without any steric clashes (Figure 7(A,B)). According to our results, 5 and $^{306}\text{VQIVYK}^{311}$, chemical interactions are comparable to those observed for orange G. Both rosmarinic acid enantiomers have the aromatic rings packed against apolar side chains of Val309 and form a hydrogen bond (HB) network with glutamine and lysine side chain groups at both sides of the steric zipper. The most important interaction is the salt link between the carboxylate group of rosmarinic acid and two Lys311 ammonium ions from $^{306}\text{VQIVYK}^{311}$ fibers.

Taken together, our docking models predict a possible interaction of 5 with $^{306}\text{VQIVYK}^{311}$ $\beta$-sheets with chemical interactions comparable to the ones reported for orange G. Therefore, we suggest that anti-aggregation effects of 5 are due to interactions with $^{306}\text{VQIVYK}^{311}$, in concordance with other reports that suggested the same mechanism for other known drugs.

Conclusions

In the present study, we isolated five compounds 1–5 from R. officinalis L. All of them demonstrated to inhibit tau aggregation over 50% at 50 $\mu$M. Moreover, we found that 5 was the most active compound. In addition, we found that both morphology and content of $\beta$ sheet is affected once we challenged tau with 5. Docking experiment revealed that 5 interact with $^{306}\text{VQIVYK}^{311}$ mainly through salt bridges. Since there is only palliative treatment against Alzheimer’s disease and tauopathies, we consider...
important to search for promising naturally compounds as potential drug pharmacophore with catechol moities.

Acknowledgements

This work was supported from INACH RT 13–13 and Fondecyt Regular No 1150745 to Alberto Cornejo and Carlos Areche. Francisco Melo, Felipe Aguilar and Leonardo Caballero kindly acknowledge Anillo ACT1412 Conicyt-Chile. George Perry acknowledges The Semmes Foundation and a grant from the National Institute on Minority Health and Health Disparities (G12MD00759) from the National Institutes of Health.

Disclosure statement

Authors declare no conflict of interest.

Figure 7. The structure of the 306VQIVYK311 segment from tau protein complexed with rosmarinic acid obtained by docking in the interface of two zippers. The VQIVYK β-sheets segments are packed in parallel forming two steric zippers. The Figure shows S mediates contacts between two pairs of steric zippers. (A) R enantiomer, (B) S enantiomer. In both A and B: left: view looks down the fiber axis; right-top: the view is perpendicular to the fiber axis. HBs and ionic interactions between ligand carboxylate and lysine amines are represented with dashed lines; right-bottom: ligand and VQIVYK carbon atoms are represented as balls to observe apolar packing.
Funding
This work was supported from INACH RT 13–13 and Fondecyt Regular No 1150745 to Alberto Cornejo and Carlos Areche. Francisco Melo, Felipe Aguilar and Leonardo Caballero kindly acknowledge Anillo ACT1412 Conicyt-Chile. George Perry acknowledges the Semmes Foundation and a grant from the National Institute on Minority Health and Health Disparities (G12MD00759) from the National Institutes of Health.

References
1. Galpern WR, Lang AE. Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol 2006;59:449–58.
2. Litvan I, Hauw JJ, Bartko JJ, et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol 1996;55:97–105.
3. Dickson DW, Bergeron C, Chin SS, et al. Office of rare diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 2002;61:935–46.
4. Kadavath H, Hofele RV, Biernat J, et al. Tau stabilizes microtubules by binding at the interface between tubulin heterodimers. Proc Natl Acad Sci USA 2015;112:7501–6.
5. Greenberg SG, Davies PA. A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc Natl Acad Sci USA 1990;87:5827–31.
6. Grundke-Iqbal I, Iqbal K, Tung YC, et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 1986;83:4913–7.
7. Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. Nat Rev Neurosci 2007;8:663–72.
8. Sawaya MR, Sanambashivan S, Nelson R, et al. Atomic structures of amyloid cross-beta spines reveal varied steric zippers. Nature 2007;447:453–7.
9. Landau M, Sawaya MR, Faull KF, et al. Towards a pharmacophore for amyloid. PLoS Biol 2011;9:e1001080.
10. Meng SR, Zhu YZ, Guo T, et al. Fibril-forming motifs are essential and sufficient for the fibrilization of human Tau. PLoS One 2012;7:e38903.
11. Plumley JA, Dannenberg JJ. Comparison of /beta-sheets of capped polyalanine with those of the tau-amyloid structures VQIVYK and VQINK. A density functional theory study. J Phys Chem B 2011;115:10560–6.
12. Peterson DW, Zhou H, Dahlquist FW, Lew J. A soluble oligomer of tau associated with fiber formation analyzed by NMR. Biochemistry 2008;47:3793–404.
13. Farias G, Cornejo A, Jimenez J, et al. Mechanisms of tau self-aggregation and neurotoxicity. Curr Alzheimer Res 2011;8:608–14.
14. Sahara N, Maeda S, Takashima A. Tau oligomerization: a role for tau aggregation intermediates linked to neurodegeneration. Curr Alzheimer Res 2008;5:591–8.
15. Oddo S, Vasilevko V, Caccamo A, et al. Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem 2006;281:39413–23.
16. Khistunova I, Biernat J, Wang Y, et al. Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J Biol Chem 2006;281:1205–14.
17. Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008;372:216–23.
18. Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9:363–72.
19. Extance A. Alzheimer’s disease raises questions about disease-modifying strategies. Nat Rev Drug Discov 2010;9:749–51.
20. Brunden KR, Trojanowski JQ, Lee VM. Advances in tau-focused drug discovery for Alzheimer’s disease and related tauopathies. Nat Rev Drug Discov 2009;8:783–93.
21. Bulic B, Pickhardt M, Schmidt B, et al. Development of tau aggregation inhibitors for Alzheimer’s disease. Angew Chem Int Ed Engl 2009;48:1740–52.
22. Kim J, Lee HJ, Lee KW. Naturally occurring phytochemicals for the prevention of Alzheimer’s disease. J Neurochem 2010;112:1415–30.
23. Porat Y, Abramowitz A, Gazit E. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Des 2006;67:27–37.
24. Bastianetto S, Krantic S, Quirion R. Polyphenols as potential inhibitors of amyloid aggregation and toxicity: possible significance to Alzheimer’s disease. Mini Rev Med Chem 2008;8:429–35.
25. Carbonaro M, DiVenere A, Filabozzi A, et al. Role of dietary antioxidant (-)-epicatechin in the development of /beta-lactoglobulin fibrils. Biochim Biophys Acta 2016;1864:766–72.
26. Shytle RD, Tan J, Bickford PC, et al. Optimized turmeric extract reduces /beta-Amyloid and phosphorylated Tau protein burden in Alzheimer’s transgenic mice. Curr Alzheimer Res 2012;9:500–6.
27. Peterson DW, George RC, Scaramozzino F, et al. Cinnamon extract inhibits tau aggregation associated with Alzheimer’s disease in vitro. J Alzheimers Dis 2009;17:585–97.
28. Cornejo A, Jimenez JM, Caballero L, et al. Fulvic acid inhibits aggregation and promotes disassembly of tau fibrils associated with Alzheimer’s disease. J Alzheimers Dis 2011;27:143–53.
29. Engberger W, Hadding U, Etschenberg E, et al. Rosmarinic acid: a new inhibitor of complement C3-convertase with anti-inflammatory activity. Int J Immunopharmacol 1988;10:729–37.
30. Aruoma OI, Spencer JP, Rossi R, et al. An evaluation of the antioxidant and antiviral action of extracts of rosemary and Provençal herbs. Food Chem Toxicol 1996;34:449–56.
31. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 2010;11:698–712.
32. Wischik CM, Harrington CR, Storey JM. Tau-aggregation inhibitor therapy for Alzheimer’s disease. Biochem Pharmacol 2014;88:529–39.
33. Dimayuga RE, Garcia SK, Nielsen PH, Christophersen C. Traditional medicine of Baja California Sur (Mexico). Ill. Carnosol: a diterpene antibiotic from Lepechinia hastata. J Ethnopharmacol 1991;31:43–8.
34. Wang M, Li J, Rangarajan M, et al. Antioxidative phenolic compounds from Sage (Salvia officinalis). J Agric Food Chem 1998;46:4869–73.
35. Schwarz K, Ternes W. Antioxidative constituents of Rosmarinus officinalis and Salvia officinalis. II. Isolation of carnosic acid and other phenolic diterpenes. Z Lebensm Unters Forsch 1992;195:99–103.

36. Pukalskas A, van Beek TA, de Waard P. Development of a triple hyphenated HPLC-radical scavenging detection-DAD-SPE-NMR system for the rapid identification of antioxidants in complex plant extracts. J Chromatogr A 2005;1074:81–8.

37. Pickhardt M, Gazova Z, von Bergen M, et al. Anthraquinones inhibit tau aggregation and dissolve Alzheimer’s paired helical filaments in vitro and in cells. J Biol Chem 2005;280:3628–35.

38. Crowe A, Ballatore C, Hyde E, et al. High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation. Biochim Biophys Res Commun 2007;358:1–6.

39. Rygula A, Majzner K, Marzec KM, et al. Raman spectroscopy of proteins: a review. J Raman Spectrosc 2013;44:1061–76.

40. Jorgensen WL, Schyman P. Treatment of halogen bonding in the OPLS-AA force field; application to potent anti-HIV agents. J Chem Theory Comput 2012;8:3895–91.

41. Eldridge MD, Murray CW, Auton TR, et al. Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J Comput Aided Mol Des 1997;11:425–45.

42. Alzate-Morales JH, Vergara-Jaque A, Caballero J. Computational study on the interaction of N1 substituted pyrazole derivatives with B-raf kinase: an unusual water wire entrance of the active site. J Chem Inf Model 2010;50:1101–12.

43. Satoh T, McKercher SR, Lipton SA. Nrf2/ARE-mediated antioxidative actions of pro-electrophilic drugs. Free Radic Biol Med 2013;65:645–57.

44. Perez-Fons L, Garzon MT, Micol V. Relationship between the antioxidant capacity and effect of rosemary (Rosmarinus officinalis L.) polyphenols on membrane phospholipid order. J Agric Food Chem 2010;58:161–71.

45. Meng P, Yoshida H, Matsumiya T, et al. Carnosic acid suppresses the production of amyloid-β-1-42 by inducing the metalloprotease gene TACE/ADAM17 in SH-SYSY human neuroblastoma cells. Neurosci Res 2013;75:94–102.

46. Yoshida H, Meng P, Matsumiya T, et al. Carnosic acid suppresses the production of amyloid-β-1-42 and 1-43 by inducing an α-secretase TACE/ADAM17 in U373MG human astrocytoma cells. Neurosci Res 2014;79:83–93.

47. Johnson JJ. Carnosol: a promising anti-cancer and anti-inflammatory agent. Cancer Lett 2011;305:1–7.

48. Johnson JJ, Syed DN, Suh Y, et al. Disruption of androgen and estrogen receptor activity in prostate cancer by a novel dietary diterpene carnosol: implications for chemoprevention. Cancer Prev Res (Phila) 2010;3:1112–23.

49. Fawcett JR, Bordayo EZ, Jackson K, et al. Inactivation of the human brain muscarinic acetylcholine receptor by oxidative damage catalyzed by a low molecular weight endogenous inhibitor from Alzheimer’s brain is prevented by pyrophosphate analogs, bioflavonoids and other antioxidants. Brain Res 2002;950:10–20.

50. Iuvone T, De Filippis D, Esposito G, et al. The spice sage and its active ingredient rosmarinic acid protect PC12 cells from amyloid-beta peptide-induced neurotoxicity. J Pharmacol Exp Ther 2006;317:1143–9.

51. Hamaguchi T, Ono K, Murase A, Yamada M. Phenolic compounds prevent Alzheimer’s pathology through different effects on the amyloid-beta aggregation pathway. Am J Pathol 2009;175:2557–65.

52. Levine H. Thioflavine-T interaction with synthetic Alzheimers-disease beta-amyloid peptides – detection of amyloid aggregation in solution. Protein Science 1993;2:404–10.

53. Di Giovanni S, Eleuteri S, Paleologou KE, et al. Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity. J Biol Chem 2010;285:14941–54.

54. Mohamed T, Hoang T, Jelokhani-Niaraki M, Rao PP. Tau-derived-hexapeptide 306VQIVYK311 aggregation inhibitors: nitrocatechol moiety as a pharmacophore in drug design. ACS Chem Neurosci 2013;4:1559–70.

55. Barghorn S, Zheng-Fischhofer Q, Ackmann M, et al. Structure, microtubule interactions, and paired helical filament aggregation by tau mutants of frontotemporal dementia. Biochemistry 2008;39:11714–21.

56. Ramachandran G, Milan-Garces EA, Udgaonkar JB, Puranik M. Resonance Raman spectroscopic measurements delineate the structural changes that occur during tau fibril formation. Biochemistry 2014;53:6550–65.

57. Wen ZQ. Raman spectroscopy of protein pharmaceuticals. J Pharm Sci 2007;96:2861–78.

58. Krimm S, Bandekar J. Vibrational spectroscopy and conformation of peptides, polypeptides, and proteins. Adv Protein Chem 1986;38:181–364.

59. Maiti NC, Apetri MM, Zagorski MG, et al., Raman spectroscopy of proteins: a review. J Raman Spectrosc 2013;44:1061–76.